(1)
GE Healthcare to scale Zionexa s FDA-approved PET imaging agent, Cerianna (fluoroestradiol F-18), used as an adjunct to biopsy for the detection of estrogen receptor (ER) positive lesions to help inform treatment selection for patients with recurrent or metastatic breast cancer
Aims to make Cerianna available to 75% of metastatic breast cancer patients in the U.S. by 2023
Acquisition demonstrates GE Healthcare s commitment to its precision health vision and builds additional pipeline of oncology and neurology tracers to help physicians personalize treatment
GE Healthcare today announced the acquisition of Zionexa, a leading innovator of in-vivo oncology and neurology biomarkers that help enable more personalized healthcare. The company aims to develop and bring to market Zionexa s pipeline biomarkers, as well as the recently FDA-approved PET imaging agent, Cerianna (fluoroestradiol F-18), which is used as an adjunct to biopsy for the detection of estrogen receptor (ER) posit
GE Healthcare Acquires Zionexa
Molecular imaging agent aims to enable more targeted treatment for metastatic breast cancer patients
May 6, 2021 GE Healthcare announced the acquisition of Zionexa, a leading innovator of in-vivo oncology and neurology biomarkers that help enable more personalized healthcare. The company aims to develop and bring to market Zionexa’s pipeline biomarkers, as well as the recently FDA-approved PET imaging agent, Cerianna (fluoroestradiol F-18), which is used as an adjunct to biopsy for the detection of estrogen receptor (ER) positive lesions to help inform treatment selection for patients with recurrent or metastatic breast cancer.
It is estimated that 168,000 people have metastatic breast cancer (“Stage 4”) in the U.S.[1], with a five-year survival rate of 28 percent[2]. Cerianna has been commercially available in the U.S. since December 2020 and today is accessible to approximately 25 percent of the relevant patient population. By leverag
GE Healthcare to scale Zionexa’s FDA-approved PET imaging agent, Cerianna (fluoroestradiol F-18),
used as an adjunct to biopsy for the detection of estrogen receptor (ER) positive lesions to help inform treatment selection for patients with recurrent or metastatic breast cancer
Aims to make Cerianna available to 75% of metastatic breast cancer patients in the U.S. by 2023
Acquisition demonstrates GE Healthcare’s commitment to its precision health vision
and builds additional pipeline of oncology and neurology tracers to
help physicians personalize treatment
6 May
2021 – GE Healthcare today announced the acquisition of Zionexa, a leading innovator of in-vivo oncology and neurology biomarkers that help enable more personalized healthcare. The company aims to develop and bring to market Zionexa’s pipeline biomarkers, as well as the recently FDA-approved PET imaging agent, Cerianna™ (fluoroestradiol F-18), which is used as an adjunct to biopsy for the detection of estrog
GE Healthcare (GE) Acquires Zionexa streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.